Norges Bank Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Norges Bank purchased a new position in Hologic, Inc. (NASDAQ:HOLXFree Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 3,044,487 shares of the medical equipment provider’s stock, valued at approximately $217,529,000. Norges Bank owned approximately 1.30% of Hologic at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Brown Advisory Inc. raised its holdings in shares of Hologic by 0.3% during the 4th quarter. Brown Advisory Inc. now owns 74,438 shares of the medical equipment provider’s stock worth $5,319,000 after acquiring an additional 192 shares in the last quarter. Independent Advisor Alliance increased its position in shares of Hologic by 28.6% during the 4th quarter. Independent Advisor Alliance now owns 4,828 shares of the medical equipment provider’s stock valued at $345,000 after purchasing an additional 1,073 shares during the last quarter. Panagora Asset Management Inc. increased its position in shares of Hologic by 2.4% during the 4th quarter. Panagora Asset Management Inc. now owns 1,106,644 shares of the medical equipment provider’s stock valued at $79,070,000 after purchasing an additional 26,349 shares during the last quarter. Triodos Investment Management BV increased its position in shares of Hologic by 4.5% during the 4th quarter. Triodos Investment Management BV now owns 23,000 shares of the medical equipment provider’s stock valued at $1,643,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Hologic by 33.2% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,436 shares of the medical equipment provider’s stock valued at $1,317,000 after purchasing an additional 4,596 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. UBS Group boosted their target price on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Raymond James upped their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. upped their price objective on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.60.

View Our Latest Stock Analysis on HOLX

Hologic Trading Up 0.3 %

Shares of NASDAQ HOLX opened at $74.81 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. The stock has a market capitalization of $17.46 billion, a P/E ratio of 38.17, a price-to-earnings-growth ratio of 2.48 and a beta of 1.01. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45. The business has a fifty day moving average price of $76.17 and a 200 day moving average price of $73.81.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the business posted $1.06 earnings per share. The firm’s revenue was down .8% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Further Reading

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.